Here, we describe a case of a patient initially presenting with metastatic SCC who underwent primary tumor resection, radiation, and four systemic therapies due to disease progression before her disease was found to harbor an ERBB2 (HER2) mutation; she was subsequently started on HER2 targeted therapy with trastuzumab and achieved a significant sustained response to treatment. The gene discussed is ERBB2; the disease is neoplasm.